New Hope Network is part of the Informa Markets Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Cognis launches Tonalin® CLA at Vitafoods

The shape of things to come at Stand 4811

Vitafoods 13/5/2003: Cognis Nutrition & Health is set to dominate the market with the launch at Vitafoods of its latest gold-standard product: Tonalin® CLA. A natural source of conjugated linoleic acid (CLA) from safflowers, Tonalin® is the original and number one selling brand of CLA worldwide.

“Now that our exclusive licensing agreement with Natural ASA is in effect, we have a great opportunity to develop the European market for Tonalin® CLA “, says Kathleen Moran, Market Segment Manager for Dietary Supplements, Cognis Nutrition & Health.

“Tonalin® has all the right elements for a successful body composition product: it’s safe and effective, and we are committed to continuing investment in both marketing support and a major programme of scientific research and education.”

Scientists at the University of Wisconsin discovered conjugated linoleic acid as a beneficial extract in 1978. On-going research has confirmed that CLA may help to maintain a healthy heart and immune system and also have a useful role to play in the management of body composition. A naturally-occurring fatty acid, it is obtained mainly through red meat and dairy fats; but as eating patterns have changed, dietary intake of CLA has declined. Converting the linoleic acid of safflower oil, a pure and natural vegetable oil, into CLA, provides an ideal alternative with potential for both dietary supplementation and food use.

Published studies - conducted exclusively on Tonalin® - show that healthy, overweight or obese people supplementing their diet with CLA decrease their body fat, while maintaining lean body mass.i Furthermore, double-blind, placebo- controlled studies have shown Tonalin® CLA to be safe and effective, without adverse side effects, at 1.8-6.8g of CLA per day for more than 12 months. The results of a long-term clinical study demonstrating a beneficial role for Tonalin® CLA on body weight management are expected to be published later this year, and further research is underway into other potential areas of benefit.

Body composition, shape and image are of particular interest in modern society, as experts voice increasing concern about the dangers of excess weight and obesity, such as increased risk of cardiovascular disease, cancer, diabetes and hypertension. The prevalence of obesity is commonly assessed by using body mass index (BMI)ii ; a BMI over 25 is defined as overweight, and BMI >30 as obese. According to the World Health Organisation - currently preparing a Global Strategy on Diet, Physical Activity and Health - there are more than 1 billion overweight adults worldwide. Excess weight is showing an unprecedented rise in the European Region, and is calculated to be responsible for over 300,000 deaths annually in the EU.iii

Cognis produces Tonalin® at its site in Illertissen in Germany, by a proprietary process (ISO 9001 compliant) that converts the linoleic acid of safflowers into conjugated linoleic acid. This triple distilled, premium quality CLA contains a high level of its two active isomers (cis-9, trans-11 and trans-10, cis-12), and its composition is exclusively licensed by the Wisconsin Alumni Research Foundation (WARF) iv. In turn, customers’ products formulated with Tonalin® are protected by WARF patents for a range of CLA applications and health benefit claims.

"The CLA retail market worldwide has seen an incredible almost 90% growth in each of the last two years,” says Duane Fimreite, Global Product Manager, Tonalin® CLA. “We expect this growth trend to continue as we expand the distribution of the Tonalin® CLA brand.” Cognis provides a high quality customer service, including expert technical and marketing support on an international and local basis. Backed by scientific studies and market research, a wide-ranging
advertising and promotional campaign throughout 2003 will increase consumer awareness of the benefits of CLA and the quality of the Tonalin® brand, building consumer demand for Tonalin® CLA by name.

Tonalin® CLA is an exclusively licensed product of the Cognis Group. For further information on Tonalin® CLA and details of Cognis international offices and contacts, visit, or e-mail

Cognis Nutrition & Health
Phone: +49 211 7940 9692
Fax: +49 211 798 2390

Cognis Nutrition & Health, a business unit of Cognis Group, provides antioxidant, botanical and nature-based ingredients for dietary supplements; pharmaceuticals and healthcare; functional foods and medical nutrition, and animal nutrition. As a leader in food technology, Cognis manufactures emulsifiers, emulsifier-based compounds and numerous other speciality products for the food industry worldwide.

Cognis Nutrition & Health is exhibiting at stand 4811 at Vitafoods International 2003, Palexpo 5, Geneva, and is also this year’s Executive Exhibition Sponsor. Seminars on Tonalin® and the science of CLA are being held in the Vitafoods theatre at 1435 on May 13th, and 1105 on May 14th.

Media Contact: Val Holmes
Phone: +44 (0)20 8979 2333
Mobile +44 (0)7775 615901 between 12-15 May 2003
About Cognis

Cognis is a worldwide supplier of innovative specialty chemicals and nutritional ingredients with almost 9,000 employees in close to 50 countries. The company has dedicated its activities to a high level of sustainability and delivers natural source raw materials and ingredients for food, nutrition and healthcare markets, and the cosmetics, detergents and cleaners industries. Additionally, Cognis provides solutions for a number of other industries, such as coatings and inks, lubricants, textiles and plastics, as well as agro and mining.

Cognis is owned by private equity funds advised by Permira, GS Capital Partners, and Schroder Ventures Life Sciences. In 2002, Cognis recorded sales of 3.1 billion euros and an operating profit before depreciation, amortization and exceptional items (EBITDA recurring) of 393 million euros.

i VERIS CLA Fact Sheet – Research Summary

ii BMI is defined as the weight in kilograms divided by the square of the height in metres (mg/m2). Further information on obesity and BMI can be found on the International Obesity Task Force website,

iii ”Food and Health in Europe,” WHO Regional Office, Europe, January 2003. WHO Fact Sheet – Obesity and Overweight.

iv Wisconsin Alumni Research Foundation, a not-for-profit organisation offering intellectual
property management services to the faculty of the University of Wisconsin, renowned for its ground breaking research in the science and technology of CLA.

Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.